Price
Target price
€43.80
€43.80
1.390%
0.6
1.390%
€48.75
18.07.24 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
There is an upward development for Agios Pharmaceuticals Inc. compared to yesterday, with an increase of €0.60 (1.390%).
With 8 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 48 € shows a slightly positive potential of 9.59% compared to the current price of 43.8 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 1.390% | 6.829% | 3.302% | 82.500% | 112.621% | -8.996% | 1.131% |
| Ironwood Pharmaceuticals | -3.250% | 0.000% | 6.250% | -37.696% | -41.667% | -46.396% | - |
| Arrowhead Pharmaceuticals Inc. | 0.550% | 0.892% | 9.053% | -19.766% | -7.599% | -54.889% | -2.910% |
| Novocure Ltd | -1.560% | 2.547% | -5.266% | -51.644% | 18.459% | -89.484% | - |
Comments
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $53.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
